Associated Papers
KEAP1 mutations activate the NRF2 pathway to drive cell growth and migration, and attenuate drug response in thyroid cancer.
Bambach NE et al.
Biorxiv : the Preprint Server for Biology, 2025
KEAP1 mutations activate the NRF2 pathway to drive cell growth and migration, and attenuate drug response in thyroid cancer.
Bambach NE et al.
Frontiers in Oncology, 2025
Development, testing and validation of a targeted NGS-panel for the detection of actionable mutations in lung cancer (NSCLC) using anchored multiplex PCR technology in a multicentric setting.
Kumbrink J et al.
Pathology Oncology Research : Por, 2024
38605929 (PubMed )
Supplement: Table1.XLSX › Sup_Table_1_Comparison_details
Clinical perspectives on the value of testing for STK11 and KEAP1 mutations in advanced NSCLC.
Shiller M et al.
Frontiers in Oncology, 2024
39703851 (PubMed )
Supplement: DataSheet2.xlsx › Supplemental_data
Indeterminate Thyroid Fine-Needle Aspirations in Pediatrics: Exploring Clinicopathologic Features and Utility of Molecular Profiling.
Baran JA et al.
Hormone Research in Paediatrics, 2022
Development of a system combining comprehensive genotyping and organoid cultures for identifying and testing genotype-oriented personalised medicine for pancreatobiliary cancers.
Shiihara M et al.
European Journal of Cancer (oxford, England : 1990), 2021
Inhibition of TXNRD or SOD1 overcomes NRF2-mediated resistance to β-lapachone.
Torrente L et al.
Redox Biology, 2020
32007910 (PubMed )
Supplement: mmc2.xlsx › Table_1_LuSCC
Molecular mechanisms of the Keap1–Nrf2 pathway in stress response and cancer evolution.
Taguchi K et al.
Genes to Cells : Devoted to Molecular & Cellular Mechanisms, 2011
Select a paper to view details